

EyeGate Pharmaceuticals

Pharma & biotech
15 March 2018

Ocular Bandage Gel awaiting return to clinic

Following positive data from its first Ocular Bandage Gel (OBG) pilot study, EyeGate has filed an amended Investigational Device Exemption (IDE) application with the FDA for a second trial. If accepted, the OBG may return to human trials in Q218. Data readouts from the trials in H218 in addition to the ongoing Phase III study for EGP-437 could prompt key value inflection drivers.

Ocular Bandage Gel supports corneal health

EyeGate's Ocular Bandage Gel is a topical eye drop based on its proprietary crosslinked thiolated carboxymethyl-hyaluronic acid (CMHA-S), a modified form of the natural polymer, hyaluronic acid (HA). HA has hydrating and healing properties when applied to the ocular surface, but it degrades rapidly. Through crosslinking, CMHA-S may adhere longer to the ocular surface and resist degradation. In Q117, EyeGate completed a pilot trial (n=39) of patients undergoing bilateral photorefractive keratectomy (PRK) surgery and found that at day 3, 83% of those receiving OBG had complete wound closure vs 54% in the standard-of-care arm.

Amended filing could lead to OBG studies in Q218

Prior to permitting the next OBG study to proceed, the FDA requested the filing of an IDE amendment detailing processes used in OBG's manufacturing to eliminate sources that could lead to contamination or raise microbial burden risk. EyeGate anticipates it could start its next PRK study (in upto 45 subjects) in H118 and it also plans another pilot OBG study in punctuate epitheliopathies (in upto 30 patients), a common sign of moderate dry eye. Each study could report data in H218 potentially leading to pivotal studies that could drive a 510(k) de novo regulatory filing in 2019.

Ocular Iontophoresis delivery system (OIDS)

EyeGate's OIDS applies a low electrical current to improve drug delivery into the eye (via electrorepulsion). EGP-437 incorporates a reformulation of corticosteroid dexamethasone with the OIDS. It is in a c 250-pt Phase III study to treat anterior uveitis, a condition that can still lead to vision loss despite treatment with the current standard-of-care (topical corticosteroids). If data is positive, the firm could submit a new drug application (NDA) under the 505(b)(2) pathway in early 2019.

Valuation: EV of \$2.2m; funding needs imminent

EyeGate had \$7.8m cash at YE17. Its 2017 net burn rate was \$6.5m, but this could increase in 2018 given the plans to start OBG studies in two indications. The firm may need to raise funds by Q318 to be on track with its planned timelines.


Historical financials

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/16	0.67	(13.34)	(1.51)	0.00	N/A	N/A
12/17	0.41	(13.22)	(0.93)	0.00	N/A	N/A

Source: Company accounts

Price **\$0.63**
Market cap **\$11m**

Share price graph



Share details

Code	EYEG
Listing	NASDAQ
Shares in issue	17.26m

Business description

EyeGate Pharmaceuticals is a specialty pharma firm developing two clinical-stage proprietary technologies for treating ocular diseases. EyeGate's OBG is being advanced for moderate dry eye and corneal wound healing. EGP-437 applies a reformulated dexamethasone to various inflammatory conditions.

Bull

- Large market opportunity in moderate dry eye
- Potential for iontophoresis platform to be extended to enable a patient-administered system to treat chronic conditions (possibly retinal edema)
- Over 3,000 treatments across multiple clinical trials suggest that EGP-437 does not significantly raise intraocular pressure, a side effect associated with prolonged corticosteroid usage

Bear

- The need to raise financing by YE18 to fulfil clinical development strategy could dilute equity holders
- High level of competition in dry eye market
- EGP-437 missed its primary endpoint in Phase IIb study (n=106) of post-cataract surgery inflammation, which raises uncertainty of its applicability for this specific indication

Analysts

Pooya Hemami, CFA	+1 (646) 653 7026
Maxim Jacobs, CFA	+1 (646) 653 7027

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.